HK1037133A1 - Conjugates for treating inflammatory disorders and associated tissue damage - Google Patents
Conjugates for treating inflammatory disorders and associated tissue damageInfo
- Publication number
- HK1037133A1 HK1037133A1 HK01107546A HK01107546A HK1037133A1 HK 1037133 A1 HK1037133 A1 HK 1037133A1 HK 01107546 A HK01107546 A HK 01107546A HK 01107546 A HK01107546 A HK 01107546A HK 1037133 A1 HK1037133 A1 HK 1037133A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- conjugates
- agent
- chemokine
- tissue damage
- inflammatory disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12052398A | 1998-07-22 | 1998-07-22 | |
PCT/CA1999/000659 WO2000004926A2 (en) | 1998-07-22 | 1999-07-21 | Conjugates for treating inflammatory disorders and associated tissue damage |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1037133A1 true HK1037133A1 (en) | 2002-02-01 |
Family
ID=22390837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01107546A HK1037133A1 (en) | 1998-07-22 | 2001-10-30 | Conjugates for treating inflammatory disorders and associated tissue damage |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP1098664B1 (de) |
JP (2) | JP4454152B2 (de) |
AT (2) | ATE347378T1 (de) |
AU (1) | AU4891899A (de) |
CA (1) | CA2335105C (de) |
DE (2) | DE69910216T2 (de) |
DK (2) | DK1098664T3 (de) |
ES (2) | ES2275999T3 (de) |
HK (1) | HK1037133A1 (de) |
IL (4) | IL140893A0 (de) |
WO (1) | WO2000004926A2 (de) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
DK1098664T3 (da) * | 1998-07-22 | 2003-11-17 | Osprey Pharmaceuticals Ltd | Sammensætninger og deres anvendelser til at behandle sekundær vævsskade og andre inflammatoriske tilstande og forstyrrelser |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
HUP0200484A2 (en) * | 1999-03-11 | 2002-06-29 | Micromet Ag | Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases |
US6358697B2 (en) * | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
CA2347371A1 (en) * | 1999-08-19 | 2001-02-22 | Genentech Inc | HEMATOPOIETIC REGULATION FACTORS AND METHODS OF USE |
US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
DE10033219A1 (de) * | 2000-07-07 | 2002-01-24 | Univ Heidelberg | Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF) |
AU2002218769A1 (en) * | 2000-07-12 | 2002-01-21 | Gryphon Therapeutics, Inc. | Chemokine receptor modulators, production and use |
RU2252786C2 (ru) * | 2000-09-08 | 2005-05-27 | Микромет Аг | Конструкции антител и хемокинов и их применение при иммунологических нарушениях |
CA2427257C (en) * | 2000-11-01 | 2014-01-21 | The Government Of The United States Of America | Expression vectors able to elicit improved immune response and methods of using same |
ATE445838T1 (de) | 2001-07-25 | 2009-10-15 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
CA2469082A1 (en) * | 2001-12-04 | 2003-06-12 | Raj K. Puri | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
IL162600A0 (en) * | 2001-12-17 | 2005-11-20 | Applied Research Systems | Cc-chemokine mutants as cc-chemokine antagonists |
US6846484B2 (en) * | 2001-12-28 | 2005-01-25 | Regents Of The University Of Minnesota | DTAT fusion toxin |
CA2869088A1 (en) | 2002-02-07 | 2003-08-14 | Massachusetts Institute Of Technology | Anti-pathogen treatments |
US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
US7695723B2 (en) | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
JP5624256B2 (ja) * | 2003-06-20 | 2014-11-12 | ラプター・ファーマシューティカル・インコーポレイテッド | 脳および他の組織への治療化合物の送達 |
US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
US7351423B2 (en) | 2004-09-01 | 2008-04-01 | Depuy Spine, Inc. | Musculo-skeletal implant having a bioactive gradient |
GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
TW200714610A (en) | 2005-02-16 | 2007-04-16 | Univ Maryland | CXCR3 is a gliadin receptor |
CA2602946A1 (en) * | 2005-03-22 | 2006-09-28 | Medstar Health, Inc. | Delivery systems and methods for diagnosing and treating cardiovascular diseases |
AU2006280004A1 (en) | 2005-08-12 | 2007-02-22 | Schering Corporation | MCP1 fusions |
WO2007041364A2 (en) * | 2005-09-30 | 2007-04-12 | Government Of The United States Of America, As Represented By The Secretary | Conjugates for modulating the immune tolerance |
EP2038302B1 (de) | 2006-07-03 | 2012-10-24 | INAGEN ApS | Immunotoxine für die behandlung von mit einer cmv-infektion in zusammenhang stehenden krankheiten |
TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
WO2008019817A1 (en) | 2006-08-17 | 2008-02-21 | F. Hoffmann-La Roche Ag | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
CA2673668A1 (en) * | 2006-12-29 | 2008-07-10 | Osprey Pharmaceuticals Usa, Inc. | Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof |
EP2062592A1 (de) * | 2007-11-20 | 2009-05-27 | BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten | System zur Abgabe in eine positive XCR1-Zelle und Verwendungen dafür |
US20110171191A1 (en) | 2008-06-12 | 2011-07-14 | Syntaxin Limited | Suppression of neuroendocrine diseases |
JP5799397B2 (ja) | 2008-06-12 | 2015-10-28 | イプセン・バイオイノベーション・リミテッドIpsen Bioinnovation Limited | 癌の抑制 |
US8524656B2 (en) | 2008-07-08 | 2013-09-03 | Jacques Galipeau | GM-CSF and truncated CCL2 conjugates and methods and uses thereof |
GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
EP2280063A1 (de) * | 2009-07-28 | 2011-02-02 | Consiglio Nazionale delle Ricerche | Pichia pastoris als Wirt zur Herstellung von dem ribosomdeaktivierendem Protein (RIP) Saporin und Fusion von Saporin mit Chimaeras |
US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
TWI487713B (zh) * | 2011-12-06 | 2015-06-11 | Nat Univ Chung Hsing | 趨化素-細胞素融合蛋白和其應用 |
GB2501611B (en) | 2012-02-21 | 2015-03-04 | Cytonics Corp | Alpha-2-macroglobulin compositions and therapeutic uses |
LT2970487T (lt) | 2013-03-12 | 2020-05-11 | Molecular Templates, Inc. | Citotoksiniai baltymai, apimantys tikslinių ląstelių rišimosi sritis ir shiga toksino subvienetų sritis, skirtas selektyviam tam tikrų rūšių ląstelių žudymui |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
ES2877356T3 (es) | 2014-01-27 | 2021-11-16 | Molecular Templates Inc | Epítopo de MHC de clase I que suministra polipéptidos |
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
CN106604934A (zh) * | 2014-06-11 | 2017-04-26 | 分子模板公司 | 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子 |
PL3242884T3 (pl) | 2015-01-09 | 2021-08-16 | Ipsen Bioinnovation Limited | Kationowe neurotoksyny |
AU2016215205B2 (en) | 2015-02-05 | 2021-10-21 | Molecular Templates, Inc. | Multivalent CD20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
EP3660035A1 (de) | 2015-05-30 | 2020-06-03 | Molecular Templates, Inc. | Deimmunisierte shigatoxin-a-untereinheitsgerüste und zellgerichtete moleküle damit |
CN105018500A (zh) * | 2015-07-01 | 2015-11-04 | 中国人民解放军第二军医大学 | 密码子优化的天花粉蛋白基因在基因治疗中的应用 |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
EP3263710A1 (de) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Herstellung von aktivierten clostridien-neurotoxinen |
KR102580647B1 (ko) | 2016-12-07 | 2023-09-20 | 몰레큘러 템플레이츠, 인코퍼레이션. | 부위 특이적 접합을 위한 시가 독소 a 서브유닛 작동체 폴리펩타이드, 시가 독소 작동체 스캐폴드, 및 세포-표적화 분자 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
CN110536695B (zh) | 2017-01-25 | 2024-05-10 | 分子模板公司 | 包括去免疫化的志贺毒素a亚基效应子和cd8+ t细胞表位的细胞靶向分子 |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
KR102095284B1 (ko) * | 2017-05-11 | 2020-04-01 | (주)케어젠 | 메토트렉세이트와 펩타이드의 결합체 |
JP7323200B2 (ja) | 2018-04-17 | 2023-08-08 | モレキュラー テンプレーツ,インク. | 脱免疫化志賀毒素aサブユニット足場を含むher2ターゲティング分子 |
AU2019301697A1 (en) * | 2018-07-13 | 2021-01-07 | Il-2Rx, Inc. | Compounds, compositions, methods, and uses for treating cancer and immunological disorders |
GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
JP7382032B2 (ja) | 2019-07-02 | 2023-11-16 | アジュ ユニバーシティー インダストリー-アカデミック コーオペレイション ファウンデーション | ヘビ毒を含む関節リウマチの予防または治療用組成物 |
GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
WO2021113328A1 (en) | 2019-12-03 | 2021-06-10 | Neuvogen, Inc. | Tumor cell vaccines |
GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
AU2021438810A1 (en) | 2021-03-30 | 2023-09-21 | Ipsen Biopharm Limited | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
BR112023020057A2 (pt) | 2021-03-30 | 2024-03-12 | Ipsen Biopharm Ltd | Tratamento de dor e distúrbios inflamatórios |
GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
CN116076438B (zh) * | 2023-03-21 | 2024-01-30 | 湖南中医药大学 | 类风湿关节炎合并间质性肺病动物模型及其构建方法和应用 |
CN117045683B (zh) * | 2023-10-12 | 2023-12-26 | 北京国卫生物科技有限公司 | 应用神经干细胞修复脊髓损伤的细胞治疗方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084556A (en) * | 1987-10-23 | 1992-01-28 | Genetics Institute, Inc. | Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene |
US5541297A (en) * | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
US5152980A (en) * | 1988-05-19 | 1992-10-06 | The Beth Israel Hospital Association | Induction of tolerance to a foreign antigen IL-2 receptor-binding substances |
US5191067A (en) * | 1989-04-27 | 1993-03-02 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
US5169934A (en) * | 1990-05-14 | 1992-12-08 | Anergen, Inc. | Intracellularly cleavable compounds |
US5326559A (en) * | 1991-05-16 | 1994-07-05 | Miller D Douglas | Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules |
WO1993025228A1 (en) * | 1992-06-15 | 1993-12-23 | Whittier Institute For Diabetes And Endocrinology | Cytotoxins specific for gm-csf receptor-bearing cells |
US5413778A (en) * | 1992-10-05 | 1995-05-09 | The Regents Of The University Of Michigan | Labelled monocyte chemoattractant protein material and medical uses thereof |
US5346686A (en) * | 1992-10-05 | 1994-09-13 | Mallinckrodt Medical, Inc. | Labelled interleukin-8 and medical uses thereof |
WO1995012414A1 (en) * | 1993-11-05 | 1995-05-11 | Repligen Corporation | Novel modified pf4 compositions and methods of use |
US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
DK1098664T3 (da) * | 1998-07-22 | 2003-11-17 | Osprey Pharmaceuticals Ltd | Sammensætninger og deres anvendelser til at behandle sekundær vævsskade og andre inflammatoriske tilstande og forstyrrelser |
-
1999
- 1999-07-21 DK DK99932572T patent/DK1098664T3/da active
- 1999-07-21 WO PCT/CA1999/000659 patent/WO2000004926A2/en active Application Filing
- 1999-07-21 IL IL14089399A patent/IL140893A0/xx unknown
- 1999-07-21 AU AU48918/99A patent/AU4891899A/en not_active Abandoned
- 1999-07-21 ES ES03076150T patent/ES2275999T3/es not_active Expired - Lifetime
- 1999-07-21 JP JP2000560919A patent/JP4454152B2/ja not_active Expired - Fee Related
- 1999-07-21 DE DE69910216T patent/DE69910216T2/de not_active Expired - Lifetime
- 1999-07-21 DE DE69934337T patent/DE69934337T2/de not_active Expired - Lifetime
- 1999-07-21 CA CA2335105A patent/CA2335105C/en not_active Expired - Fee Related
- 1999-07-21 DK DK03076150T patent/DK1346731T3/da active
- 1999-07-21 ES ES99932572T patent/ES2205849T3/es not_active Expired - Lifetime
- 1999-07-21 AT AT03076150T patent/ATE347378T1/de active
- 1999-07-21 EP EP99932572A patent/EP1098664B1/de not_active Expired - Lifetime
- 1999-07-21 AT AT99932572T patent/ATE246517T1/de active
- 1999-07-21 EP EP03076150A patent/EP1346731B1/de not_active Expired - Lifetime
-
2001
- 2001-01-10 IL IL140893A patent/IL140893A/en not_active IP Right Cessation
- 2001-10-30 HK HK01107546A patent/HK1037133A1/xx not_active IP Right Cessation
-
2007
- 2007-11-15 IL IL187389A patent/IL187389A/en not_active IP Right Cessation
- 2007-11-15 IL IL187388A patent/IL187388A/en not_active IP Right Cessation
-
2009
- 2009-11-19 JP JP2009264178A patent/JP2010075194A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL187388A (en) | 2010-06-30 |
IL140893A0 (en) | 2002-02-10 |
ES2275999T3 (es) | 2007-06-16 |
DE69910216T2 (de) | 2004-02-19 |
IL187389A (en) | 2010-06-30 |
EP1098664A2 (de) | 2001-05-16 |
WO2000004926A2 (en) | 2000-02-03 |
ATE347378T1 (de) | 2006-12-15 |
IL140893A (en) | 2010-06-16 |
DE69934337T2 (de) | 2007-05-24 |
IL187389A0 (en) | 2008-02-09 |
CA2335105A1 (en) | 2000-02-03 |
EP1346731A1 (de) | 2003-09-24 |
WO2000004926A3 (en) | 2000-11-02 |
DE69910216D1 (de) | 2003-09-11 |
AU4891899A (en) | 2000-02-14 |
DE69934337D1 (de) | 2007-01-18 |
IL187388A0 (en) | 2008-02-09 |
JP2010075194A (ja) | 2010-04-08 |
CA2335105C (en) | 2010-05-11 |
ATE246517T1 (de) | 2003-08-15 |
JP4454152B2 (ja) | 2010-04-21 |
DK1098664T3 (da) | 2003-11-17 |
JP2002521019A (ja) | 2002-07-16 |
ES2205849T3 (es) | 2004-05-01 |
DK1346731T3 (da) | 2007-04-10 |
EP1098664B1 (de) | 2003-08-06 |
EP1346731B1 (de) | 2006-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1037133A1 (en) | Conjugates for treating inflammatory disorders and associated tissue damage | |
CA2310850A1 (en) | A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia | |
ATE383430T1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
WO1997044063A3 (en) | Dha-pharmaceutical agent conjugates | |
EP2283867A3 (de) | Methoden zur Behandlung unter Verwendung von ERBB Antibody-Mayntasinoid Konjugate | |
WO2001070275A3 (en) | Polyglutamic acid-camptothecin conjugates and methods of preparation | |
WO2004111192A3 (en) | Targeted delivery to legumain-expressing cells | |
MY131095A (en) | Polyethylene protein conjugates. | |
ATE296105T1 (de) | Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel | |
MA30689B1 (fr) | Derives de leptomycine | |
WO2003009815A3 (en) | Compositions and methods for modulating blood-brain barrier transport | |
WO2003068144A3 (en) | Cytotoxic agents | |
EP1507556A4 (de) | Calicheamicin-derivat-trägerkonjugate | |
WO2001082899A3 (en) | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites | |
BR9811094A (pt) | Agente terapêutico para tumores linfáticos | |
HK1051964A1 (en) | G-csf conjugates g-csf | |
WO2002076402A3 (en) | Fatty amine drug conjugates | |
EP0978265A3 (de) | Wegwerfwindel | |
WO1997023240A3 (de) | Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether | |
PT1107793E (pt) | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados | |
DE69700983D1 (de) | Ligandgerichtete enzyme-prodrug therapie | |
PL340459A1 (en) | Agonists of 5ht1f | |
IL154324A0 (en) | Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis | |
IL156069A0 (en) | Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma | |
WO2001040239A3 (en) | Transition metal-cyclopentadienyl-tropane conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20120721 |